| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8281ac9f4fb11f15a5da018344453338
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e52d326080d9aabcbf9e0613b3e5357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6ae224073fa9ba2acc22ba3a80c75b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15a1f58e176ed86ee706545002dd4649 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1027 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 |
| filingDate |
2008-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92acd2569a876ce60bd7416cca046cb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d06cd962df86d3ef1392ab74bbf2aa3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95ee3e0e646c225af0e764532a44b5ab |
| publicationDate |
2012-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8324155-B2 |
| titleOfInvention |
Quinoxaline-containing compounds as hepatitis C virus inhibitors |
| abstract |
The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: n nwhich inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8951998-B2 |
| priorityDate |
2007-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |